Two-Loop Helicity Amplitudes for Quark-Gluon Scattering in QCD and Gluino-Gluon Scattering in Supersymmetric Yang-Mills Theory

We present the two-loop QCD helicity amplitudes for quark-gluon scattering, and for quark-antiquark annihilation into two gluons. These amplitudes are relevant for next-to-next-to-leading order corrections to (polarized) jet production at hadron colliders. We give the results in the `t Hooft-Veltman and four-dimensional helicity (FDH) variants of dimensional regularization. The transition rules for converting the amplitudes between the different variants are much more intricate than for the previously discussed case of gluon-gluon scattering. Summing our two-loop expressions over helicities and colors, and converting to conventional dimensional regularization, gives results in complete agreement with those of Anastasiou, Glover, Oleari and Tejeda-Yeomans. We describe the amplitudes for 2 to 2 scattering in pure N=1 supersymmetric Yang-Mills theory, obtained from the QCD amplitudes by modifying the color representation and multiplicities, and verify supersymmetry Ward identities in the FDH scheme.Comment: 77 pages. v2: corrected errors in eqs. (3.7) and (3.8) for one-loop assembly; remaining results unaffecte

Multimessenger astronomy with the Einstein Telescope

Gravitational waves (GWs) are expected to play a crucial role in the development of multimessenger astrophysics. The combination of GW observations with other astrophysical triggers, such as from gamma-ray and X-ray satellites, optical/radio telescopes, and neutrino detectors allows us to decipher science that would otherwise be inaccessible. In this paper, we provide a broad review from the multimessenger perspective of the science reach offered by the third generation interferometric GW detectors and by the Einstein Telescope (ET) in particular. We focus on cosmic transients, and base our estimates on the results obtained by ET's predecessors GEO, LIGO, and Virgo.Comment: 26 pages. 3 figures. Special issue of GRG on the Einstein Telescope. Minor corrections include

Rhesus macaques self-curing from a schistosome infection can display complete immunity to challenge

To date there is only one single drug with modest efficacy and no vaccine available to protect from schistosomiasis. Here, Amaral et al. characterize the self-cure process of rhesus macaques following primary infection and secondary challenge with Schistosoma mansoni to inform future vaccine development studies.The rhesus macaque provides a unique model of acquired immunity against schistosomes, which afflict >200 million people worldwide. By monitoring bloodstream levels of parasite-gut-derived antigen, we show that from week 10 onwards an established infection with Schistosoma mansoni is cleared in an exponential manner, eliciting resistance to reinfection. Secondary challenge at week 42 demonstrates that protection is strong in all animals and complete in some. Antibody profiles suggest that antigens mediating protection are the released products of developing schistosomula. In culture they are killed by addition of rhesus plasma, collected from week 8 post-infection onwards, and even more efficiently with post-challenge plasma. Furthermore, cultured schistosomula lose chromatin activating marks at the transcription start site of genes related to worm development and show decreased expression of genes related to lysosomes and lytic vacuoles involved with autophagy. Overall, our results indicate that enhanced antibody responses against the challenge migrating larvae mediate the naturally acquired protective immunity and will inform the route to an effective vaccine.Cancer Signaling networks and Molecular Therapeutic

Primeiro registro de epidemias causadas pelo vírus Oropouche nos Estados do Maranhão e Goiás, Brasil

Os autores descrevem a ocorrência de epidemias causadas pelo vírus Oropouche (ORO) nos Estados do Maranhão (MA) e Goiás (GO) em 1988. 36 amostras de vírus foram obtidas a partir da inoculação do sangue de 120 pacientes em camundongos recém nascidos. A doença foi caracterizada por febre, cefaléia, dores musculares, articulares, fotofobia, dor retro ocular, náuseas e tontura. 128 das 197 pessoas examinadas em Porto Franco, MA, tinham anticorpos inibidores da hemaglutinação (IH) para o agente e, em 106 foram detectados anticorpos IgM por MAC ELISA. Todos os grupos etários foram infectados, embora a incidência tenha sido mais elevada entre aqueles com 10 a 19 anos de idade. Quanto ao sexo, a infecção ocorreu igualmente em ambos os sexos. Recorrência dos sintomas foi observada em 56% dos casos positivos estudados. A inoculação em camundongos Swiss recém nascidos de 3.624 Culicoides paraensis (Ceratopogonidae) e 1.970 Culex (Culex) quinquefasciatus (Culicidae), coletados em Porto Franco-MA, resultou em um único isolamento do vírus ORO a partir dos Culicoides. Essa é a primeira descrição de casos confirmados de infecção pelo vírus Oropouche nos Estados do Maranhão e Goiás, Brasil

Resposta da produtividade de grãos e outras características agronômicas do trigo EMBRAPA-22 irrigado ao nitrogênio em cobertura

As doses e a época de aplicação do nitrogênio (N) podem influenciar as características agronômicas do trigo (Triticum aestivum L.) irrigado e, conseqüentemente, a produtividade de grãos. Neste sentido, foram instalados dois experimentos na Estação Experimental da Universidade Federal de Viçosa, localizada em Coimbra (MG), em 1995 e 1996. Os tratamentos foram constituídos pela combinação de quatro doses de N (30, 60, 90 e 120 kg ha-1), quatro formas de parcelamento (dose total aos 20 dias da emergência (DAE); ½ aos 20 + ½ aos 40 DAE; 1/3 aos 20 + 2/3 aos 40 DAE e 2/3 aos 20 + 1/3 aos 40 DAE) e uma testemunha (sem N em cobertura), dispostos em esquema fatorial 4 x 4 + 1, no delineamento em blocos casualizados com quatro repetições. A altura e o acamamento das plantas, a biomassa seca, o índice de colheita, a massa de mil grãos, o peso hectolítrico e a produtividade de grãos foram influenciados pelas doses de N. Em 1996, o número de espigas por metro quadrado e o número de perfilhos férteis por planta diminuíram, em conseqüência do acamamento precoce das plantas, enquanto o número de grãos por espiga e o número de grãos por metro quadrado aumentaram com o incremento nas doses de N. As formas de parcelamento influenciaram somente o acamamento das plantas

Epidemiology of surgery associated acute kidney injury (EPIS-AKI) : a prospective international observational multi-center clinical study

The incidence, patient features, risk factors and outcomes of surgery-associated postoperative acute kidney injury (PO-AKI) across different countries and health care systems is unclear. We conducted an international prospective, observational, multi-center study in 30 countries in patients undergoing major surgery (> 2-h duration and postoperative intensive care unit (ICU) or high dependency unit admission). The primary endpoint was the occurrence of PO-AKI within 72 h of surgery defined by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Secondary endpoints included PO-AKI severity and duration, use of renal replacement therapy (RRT), mortality, and ICU and hospital length of stay. We studied 10,568 patients and 1945 (18.4%) developed PO-AKI (1236 (63.5%) KDIGO stage 1500 (25.7%) KDIGO stage 2209 (10.7%) KDIGO stage 3). In 33.8% PO-AKI was persistent, and 170/1945 (8.7%) of patients with PO-AKI received RRT in the ICU. Patients with PO-AKI had greater ICU (6.3% vs. 0.7%) and hospital (8.6% vs. 1.4%) mortality, and longer ICU (median 2 (Q1-Q3, 1-3) days vs. 3 (Q1-Q3, 1-6) days) and hospital length of stay (median 14 (Q1-Q3, 9-24) days vs. 10 (Q1-Q3, 7-17) days). Risk factors for PO-AKI included older age, comorbidities (hypertension, diabetes, chronic kidney disease), type, duration and urgency of surgery as well as intraoperative vasopressors, and aminoglycosides administration. In a comprehensive multinational study, approximately one in five patients develop PO-AKI after major surgery. Increasing severity of PO-AKI is associated with a progressive increase in adverse outcomes. Our findings indicate that PO-AKI represents a significant burden for health care worldwide

Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050

Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached$8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total,$40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this,$13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and$1.4 billion was repurposed from existing health projects. $3.1 billion (22.4$2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7$1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe